위식도 역류증 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Gastroesophageal Reflux Disease Therapeutics Market size is expected to reach USD 7.56 Billion in 2034 from USD 5.83 Billion (2025) growing at a CAGR of 2.93% during 2026-2034.

The Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market is witnessing steady growth due to increasing incidence of acid reflux and digestive disorders globally. Sedentary lifestyles, unhealthy eating habits, obesity, and stress are major contributors to rising GERD cases. The growing availability of effective medications, including proton pump inhibitors (PPIs) and H2 receptor antagonists, is driving consistent demand.

Key growth drivers include improved diagnostic procedures, growing healthcare awareness, and easy availability of over-the-counter medications. Pharmaceutical companies are investing in extended-release and combination therapies to enhance treatment outcomes. Expanding healthcare infrastructure and rising geriatric populations in both developed and developing regions are further supporting market growth.

In the future, the market is expected to expand with the development of novel drug formulations and minimally invasive treatment options. Research into targeted therapies and improved patient compliance strategies will strengthen treatment effectiveness. Emerging markets with increasing healthcare access and awareness are projected to create significant opportunities for GERD therapeutic manufacturers.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Proton Pump Inhibitors (PPIs)
• H2 Receptor Antagonists (H2RAs)
• Antacids
• Prokinetic Agents
• Other Drug Classes

By Route of Administration

• Oral
• Injectable

By Stage

• Stage 1
• Stage 2
• Stage 3
• Stage 4

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AstraZeneca, Camber Pharmaceuticals, Eisai, Johnson Johnson, Onconic Therapeutics, Pfizer, Phathom Pharmaceuticals, Sebela Pharmaceuticals, Takeda Pharmaceutical Company, Teva Pharmaceuticals, Viatris
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Proton Pump Inhibitors (PPIs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. H2 Receptor Antagonists (H2RAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antacids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Prokinetic Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY STAGE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Stage
• 6.2. Stage 1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Stage 2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Stage 3 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Stage 4 Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Stage
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Stage
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Stage
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Stage
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Stage
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AstraZeneca
  • 10.2.2 Camber Pharmaceuticals
  • 10.2.3 Eisai
  • 10.2.4 Johnson & Johnson
  • 10.2.5 Onconic Therapeutics
  • 10.2.6 Pfizer
  • 10.2.7 Phathom Pharmaceuticals
  • 10.2.8 Sebela Pharmaceuticals
  • 10.2.9 Takeda Pharmaceutical Company
  • 10.2.10 Teva Pharmaceuticals
  • 10.2.11 Viatris